BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
2025 Arctic League telethon raises more than $39k - 2Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- 3Overlooked infertility care should be part of national health services, says WHO
- 4The most effective method to Recognize a Great Lab Jewel
- 5Real time features for Films and Programs
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- Top 15 Style Creators Changing the Business
- Figure out How to Explore Land Close to 5G Pinnacles
- Instructions to Explore the Universe of Vehicle Leases
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
